The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...

Medical device maker Dexcom said on Tuesday it will invest $75 million in Ōura's latest funding round, valuing the smart ring maker at over $5 billion.

subscribe to our free daily MedTech Dive newsletter. The second wave of the medtech industry’s latest earnings season arrives this week, with Boston Scientific, Edwards Lifesciences and Dexcom ...

Medtronic (NYSE: MDT) Q2 2025 Earnings Call Nov 19, 2024, 8:00 a.m. ET ...

Following an eight-day trial in which the U.S. Federal Trade Commission ... Finding a qualified financial advisor doesn't have to be hard. SmartAsset's free tool matches you with up to three ...

Wearable diagnostics are poised to transform subjective, episodic measures of disease progression to quantified, continuous data streams, according to some industry experts.

Abbot dropped by 2.9%, while Dexcom dropped 5.3%. For now, Apple is testing ways the information can be applied, but a truly stick-free way of measuring blood sugar is “still years away ...

Last quarter, we announced the full market release of Omnipod 5 with Dexcom's G7 in the U.S., starting ... profitable growth and positive free cash flow is paying up, resulting in our ability ...

Also, Boeing fell -1.69% after reporting larger-than-expected negative Q3 adjusted free cash flow. In addition ... fell -0.56% after saying during an earnings call that it is pausing a trial of its ...

DexCom invests $75M in Finnish health tech firm ŌURA, forming a strategic partnership to integrate glucose data with vital signs and biometrics.

Smart ring maker Oura and glucose monitoring giant Dexcom just struck a partnership that will allow the company's products to ...